Lefer D J, Flynn D M, Buda A J
Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
Am J Physiol. 1996 Jan;270(1 Pt 2):H88-98. doi: 10.1152/ajpheart.1996.270.1.H88.
Neutrophils (polymorphonuclear leukocytes, PMNs) play a role in tissue injury after ischemia and reperfusion. We investigated the effects of a monoclonal antibody (MAb), PB1.3, directed against P-selectin in an acute model of myocardial ischemia-reperfusion injury. Dogs were subjected to 120 min of coronary arterial occlusion and 240 min of reperfusion. MAb PB1.3 (1 mg/kg), the nonblocking P-selectin antibody, MAb PNB1.6 (1 mg/kg), or saline was administered 5 min before reperfusion. Dogs treated with saline (n = 7), MAb PB1.3 (n = 7), and MAb PNB1.6 (n = 5) all experienced similar myocardial blood flows during ischemia, and treatment with MAb PB1.3 failed to preserve postischemic myocardial blood flow. Measurement of myocardial contractility failed to demonstrate any beneficial effects of MAb PB1.3 on postischemic myocardial contractility. However, myocardial necrosis (% of area at risk) was significantly reduced (P < 0.01) in dogs receiving MAb PB1.3 (20.8 +/- 4.8%) compared with dogs receiving either normal saline (41.7 +/- 4.5%) or MAb PNB1.6 (46.7 +/- 7.6%). Myocardial myeloperoxidase activity in the ischemic zone was 4.8 +/- 0.6 in the vehicle group and 3.7 +/- 0.5 in the MAb PNB1.6 group compared with 2.0 +/- 0.5 in MAb PB1.3-treated dogs (P < 0.01 vs. saline; P < 0.05 vs. PNB1.6). In summary, treatment with MAb PB1.3 failed to preserve postischemic myocardial blood flow or myocardial contractility. In contrast, P-selectin immunoneutralization reduced PMN accumulation and myocardial tissue injury in a canine model of coronary occlusion and reperfusion.
中性粒细胞(多形核白细胞,PMNs)在缺血再灌注后的组织损伤中起作用。我们在心肌缺血-再灌注损伤的急性模型中研究了一种针对P-选择素的单克隆抗体(MAb)PB1.3的作用。对犬进行120分钟的冠状动脉闭塞和240分钟的再灌注。在再灌注前5分钟给予MAb PB1.3(1mg/kg)、非阻断性P-选择素抗体MAb PNB1.6(1mg/kg)或生理盐水。用生理盐水治疗的犬(n = 7)、MAb PB1.3治疗的犬(n = 7)和MAb PNB1.6治疗的犬(n = 5)在缺血期间均经历了相似的心肌血流,并且用MAb PB1.3治疗未能维持缺血后心肌血流。心肌收缩力的测量未能证明MAb PB1.3对缺血后心肌收缩力有任何有益作用。然而,与接受生理盐水(41.7±4.5%)或MAb PNB1.6(46.7±7.6%)的犬相比,接受MAb PB1.3的犬心肌坏死(危险区域面积的百分比)显著降低(P < 0.01)(20.8±4.8%)。缺血区心肌髓过氧化物酶活性在载体组为4.8±0.6,在MAb PNB1.6组为3.7±0.5,而在MAb PB1.3治疗的犬中为2.0±0.5(与生理盐水相比,P < 0.01;与PNB1.6相比,P < 0.05)。总之,用MAb PB1.3治疗未能维持缺血后心肌血流或心肌收缩力。相比之下,在犬冠状动脉闭塞和再灌注模型中,P-选择素免疫中和减少了PMN积聚和心肌组织损伤。